Lightnews — Scholar-powered news

The Science of Parkinson's @scienceofpd.bsky.social · 21h

Looking forward to the @cureparkinsons.org.uk Autumn Research Update meeting; It is FREE (virtual & in-person); Come along & learn what we are funding in #Parkinsons research (big theme for this meeting will be MAMS - multi-arm, multi-stage trial platforms)
cureparkinsons.org.uk/2025/10/autu...

Autumn Research Update Meeting 2025 - Cure Parkinson's

Our 2025 Autumn Research Update Meeting will take place once again at the renowned Royal Society of Medicine (RSM), Wimpole Street, London, on Monday 10

cureparkinsons.org.uk

1 3

The Science of Parkinson's @scienceofpd.bsky.social · 21h

Researchers present the core clinical features associated with survival in patients with Dementia with Lewy Bodies
www.neurology.org/doi/10.1212/...

Core Clinical Features Associated With Survival in Patients With Dementia With Lewy Bodies | Neurology

Background and ObjectivesThis analysis used clinical data from prospectively followed participants meeting criteria for probable dementia with Lewy bodies (DLB) in the Mayo Clinic Alzheimer's Disease ...

www.neurology.org

The Science of Parkinson's @scienceofpd.bsky.social · 21h

New review article explores targeting metabotropic glutamate receptors for symptomatic & disease-modifying treatment in #Parkinsons
www.nature.com/articles/s41...

The Science of Parkinson's @scienceofpd.bsky.social · 21h

Everything you ever wanted to know about mitochondria-associated membranes - a new review explores molecular organization, cellular functions, & their role in health + disease ( #Parkinsons get a few mentions)
febs.onlinelibrary.wiley.com/doi/10.1002/...

1 2

The Science of Parkinson's @scienceofpd.bsky.social · 21h

Using an unbiased FACS-based genome-wide CRISPR/Cas9 knockout screen, researchers identify key genes & pathways specifically implicated in α-syn PFFs intracellular accumulation, including heparan sulfate proteoglycans biosynthesis & Golgi trafficking
www.nature.com/articles/s42...

1 2

The Science of Parkinson's @scienceofpd.bsky.social · 1d

Researchers present a novel lncRNA FAM151B-DT that regulates degradation of aggregation prone proteins; Silencing FAM151B-DT in vitro is sufficient to enhance tau & #Parkinsons-associated α-synuclein aggregation
www.nature.com/articles/s41...

The Science of Parkinson's @scienceofpd.bsky.social · 1d

The age association aspect of #Parkinsons does not get enough attention.

Now researchers provide a framework to enhance research reproducibility, investigating the nexus of ageing & PD
www.nature.com/articles/s41...

The Science of Parkinson's @scienceofpd.bsky.social · 1d

Interesting: LRRK2 inhibitors for #Alzheimers?

Researchers report LRRK2 deficiency mitigates amyloid β deposition-mediated pathology in a mouse model of AD (by reprogramming microglia)
www.nature.com/articles/s41...

1

The Science of Parkinson's @scienceofpd.bsky.social · 1d

Last week Herantis Pharma presented positive topline data from their Phase 1b trial of small peptide molecule HER-096 (designed to mimic the activity of cerebral dopamine neurotrophic factor; CDNF) in people with #Parkinsons at MDS2025
herantis.com/news-events/...

The Science of Parkinson's @scienceofpd.bsky.social · 1d

The new tube map of London - called the "Expobiome map"

1

The Science of Parkinson's @scienceofpd.bsky.social · 1d

Meta-metabolomics?!?

Ok

If that is what it takes

Researchers identify 11 metabolites that are differentially abundant between #Parkinsons (n=50), prodromal PD (n=30) & control cases (n=50); β-glutamate⬆️in PD and prodromal PD
microbiomejournal.biomedcentral.com/articles/10....

1

The Science of Parkinson's @scienceofpd.bsky.social · 1d

Curiously, dopamine agonist-treated cases of restless leg syndrome (n = 3077) showed a significantly longer restricted mean survival time to #Parkinsons diagnosis, compared to controls

The Science of Parkinson's @scienceofpd.bsky.social · 1d

New retrospective cohort study using Korean National Health Insurance Service data (2002 to 2019) finds restless leg syndrome is associated with an increased risk of developing #Parkinsons; N=9919 patients with RLS & 9919 matched controls
jamanetwork.com/journals/jam...

1

The Science of Parkinson's @scienceofpd.bsky.social · 4d

New research presents a comprehensive genetic catalog of both known & novel coding & splicing variants potentially linked to #Parkinsons etiology in 710 African cases (& 11k controls)
academic.oup.com/brain/advanc...

The Science of Parkinson's @scienceofpd.bsky.social · 4d

Oh look! Speaking of combos

A new funding opportunity to explore rationally designed combination therapies in #Parkinsons

How interesting!
cureparkinsons.org.uk/2025/09/new-...

New funding opportunity: Combination therapies for Parkinson’s - Cure Parkinson's

Cure Parkinson’s is excited to announce that we are now accepting expressions of interest for our new combination therapy funding call. In August, Cure

cureparkinsons.org.uk

3

The Science of Parkinson's @scienceofpd.bsky.social · 4d

Combination therapies! #Alzheimers is doing it, why isn't #Parkinsons?

Human transcriptomic & drug repurposing analyses identify letrozole & irinotecan for AD; Medical records=⬇️lower AD risk in people exposed to letrozole or irinotecan; Combo rescues AD models
www.cell.com/cell/fulltex...

1 1

The Science of Parkinson's @scienceofpd.bsky.social · 7d

The intervention was prescribed stationary cycling for 45 minutes 3x per week, with virtual coaching "focused on maintaining a high-rate cadence (≥75 RPMs)" - need more info on this

1

The Science of Parkinson's @scienceofpd.bsky.social · 7d

More data from the #MDS2025 meeting: Arvinas reports positive Phase 1 clinical data for ARV-102 (their PROTAC LRRK2 degrader); 14 days of treatment in healthy volunteers & #people with #Parkinsons; >90%⬇️of LRRK2 protein in PBMCs & >50%⬇️in CSF
ir.arvinas.com/news-release...

The Science of Parkinson's @scienceofpd.bsky.social · 7d

For more information about the study: clinicaltrials.gov/study/NCT040...

ClinicalTrials.gov

clinicaltrials.gov

1

The Science of Parkinson's @scienceofpd.bsky.social · 7d

"Cycling regimen demonstrated a significantly lower rate of motor symptom progression at 12 months than those receiving usual care, as rated by the MDS-UPDRS Part III scale (+3.7 points; P<0.0001)"; 93% adherence, with study participants completing 92.4 min exercise per week

2

The Science of Parkinson's @scienceofpd.bsky.social · 7d

Data reported at the #MDS2026 meeting from the randomized controlled CYCLE-II trial: researchers report 12-month home-based high-intensity exercise intervention=lower rate of motor symptom progression (UPDRS-3) in 256 people with mild-to-mod #Parkinsons
www.prnewswire.com/news-release...

1 1

The Science of Parkinson's @scienceofpd.bsky.social · 7d

The protocol for the Modified Mediterranean diet effects on #Parkinsons disease (MED-PARK - a single-centre randomised controlled trial evaluating the efficacy & safety of a modified Mediterranean diet on motor & non-motor symptoms) has been published
bmjopen.bmj.com/content/15/1...

Modified Mediterranean diet effects on Parkinson’s disease (MED-PARK): a single-centre randomised controlled trial protocol

Introduction Only symptomatic treatments are available for patients with Parkinson’s disease (PD), the second most common chronic neurodegenerative disease worldwide, and it is therefore imperative to...

bmjopen.bmj.com

The Science of Parkinson's @scienceofpd.bsky.social · 7d

But now "ABLi Therapeutics" is announcing at the 2025MDS meeting that the results from the same 12 week (?) trial (NCT05424276) "demonstrates potential functional benefit in early #Parkinsons"...
www.neurologylive.com/view/risvode...

Risvodetinib Demonstrates Potential Functional Benefit in Early Parkinson Disease | NeurologyLive - Clinical Neurology News and Neurology Expert Insights

A phase 2 study shows risvodetinib improves safety and symptoms in early Parkinson disease, suggesting potential as a disease-modifying therapy.

www.neurologylive.com

The Science of Parkinson's @scienceofpd.bsky.social · 7d

I'm confused:
In early 2025, Inhibikase announced that while their c-ABL inhibitor risvodetinib (IkT148009) was safe & tolerable (primary end point) in untreated PD, but "did not demonstrate an improvement in the top hierarchical efficacy measure" in any dose group vs placebo

1

The Science of Parkinson's @scienceofpd.bsky.social · 9d

New research identifies the protein phosphatase PP2A-B55α/PPP2R2A as a Parkin-dependent regulator of mitochondrial number; PP2A-B55α targeting rescues neurodegenerative phenotypes in a fly model of #Parkinsons
www.science.org/doi/10.1126/...

2